3 results
Approved WMORecruiting
To determine the effect of lithium treatment (plasma levels between 0,4-0,8 mEq/liter) versus placebo - in addition to riluzole 2dd 50 mg - on reaching a clinical endpoint in patients with ALS.
Approved WMORecruiting
Part A: Safety:• To characterize the safety and tolerability of up to four dose levels of rilzabrutinibin patients with ITPEfficacy:• To explore the clinical activity of up to four dose levels of rilzabrutinibin relapsed/refractory patients with ITP…
Approved WMORecruiting
To investigate the efficacy and safety of drugs for patients with ALS.